RECENT COMMENTS

Cheryl-Anne Simoneau (Jan Geissler): Great article Jan. It is a pleasure to work with you. We face many of the same challenges here in [...]   »Read more

Kathi Apostolidis: Susan, your article sheds light on a still underdiscussed, if discussed at all, issue for younger pa [...]   »Read more

Dipl.-Ing. Christian Ligensa: Dr. Peter Caroll, Head of Urology at UCSF and Editor of the Journal of Urology published in the Edit [...]   »Read more

Kathi Apostolidis: Thanks Jan, for bringing up issues such as pharma funding, learning needs, networking capacity of pa [...]   »Read more

stella kyriakides: thank you Jan, all the above challenges you mention are even greater in the case of the rarer cncer [...]   »Read more

 
 

e-ESO.net

E-eso

Online educational resources Including e-grandrounds, weekly online meetings in collaboration with Nature Reviews Clinical Oncology - CME accredited!

Next live sessions:

GR84 - Pitfalls and uncommon problems in thyroid cancer management

GR85 - Minimally invasive surgery for the treatment of prostate cancer: Myth and reality

GR86 - Improve training opportunities for cancer control professionals (in co-operation with UICC www.uicc.org)

The website is supported by an unrestricted educational grant provided by:

Founding sponsor

CancerWorld invites you to visit:

E-eso
European School of Oncology -
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.
E-aso
Euro-Arab School of Oncology - is a joint initiative between the Egyptian Ministry of Health and Population and ESO. EASO intends to enhance and support education in the oncology field in all the Arab countries.
 
ECPC
ECPC
Europa Donna
Europa
Donna
Europa Uomo
Europa
Uomo
EONS
EONS
SIOG
SIOG
The challenge Fund
The
Challenge
Fund
Seno network
SenoNetwork
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, AstraZeneca, Eli Lilly, GlaxoSmithKline, Merck and Novartis.